Key terms
About KTRA
Kintara Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. Its product pipeline includes VAL-083 and REM-001. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest KTRA news
Apr 03
7:49am ET
Kintara Merges with TuHURA to Advance Cancer Therapy
Apr 03
7:30am ET
Kintara Therapeutics, TuHURA Biosciences enter merger agreement
Apr 03
7:22am ET
Kintara Therapeutics Announces Strategic Acquisition of TuHURA Biosciences
Apr 03
7:07am ET
Kintara Therapeutics and TuHURA Biosciences sign definitive merger agreement
Mar 27
9:03am ET
Kintara Therapeutics expands inclusion criteria in REM-001 study
Feb 22
7:14am ET
Kintara Therapeutics Halts ATM Offerings and Equity Facility Usage
Feb 14
4:25pm ET
Kintara Therapeutics Issues Unofficial Financial Update
Feb 12
9:23am ET
Kintara Advances CMBC Treatment with REM-001 Clinical Trial
Feb 12
9:05am ET
Kintara Therapeutics initiates REM-001 15-patient clinical trial
KTRA Financials
Key terms
Ad Feedback
KTRA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
KTRA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
